
What they do:
AI Scribe for veterinarians. Saving time and improving patient care.
Quick facts:
HQ: Seattle, WA, United States
This list has 13 startups and was last updated on Oct 15, 2026. 2 of them are hiring right now. Largest teams: VetRec, Talus Bio, and Rebellyous Foods. Latest round: Bonum Therapeutics raised $26.9M (Apr 17, 2026).

What they do:
AI Scribe for veterinarians. Saving time and improving patient care.
Quick facts:
HQ: Seattle, WA, United States

What they do:
Discovering drugs that target the DNA regulome
Quick facts:
HQ: Seattle, WA, United States

What they do:
Rebellyous Foods is a food manufacturing technology and production…
Quick facts:
HQ: Seattle, WA, United States

What they do:
The first test designed to prevent birth control side effects
Quick facts:
HQ: Seattle, WA, United States

What they do:
BloomAPI helps doctors share clinical data. Today most healthcare…
Quick facts:
HQ: Seattle, WA, United States

What they do:
AI-native retrieval engine for medical records
Quick facts:
HQ: Seattle, WA, United States

What they do:
Sigma Genetics is a biotechnology company that is building…
Quick facts:
HQ: Seattle, WA, United States

What they do:
AI automated prior-auths for private medical practices
Quick facts:
HQ: Seattle, WA, United States

What they do:
Home medical equipment, prescribed online and delivered.
Quick facts:
HQ: Seattle, WA, United States
Quick facts:
HQ: Seattle, WA, United States
Funding:
$26.9M · Equity · Apr 2026

What they do:
Makers of simple, affordable medical devices. Our award-winning…
Quick facts:
HQ: Seattle, WA, United States

What they do:
Large Scale Genomic Data Mining Software
Quick facts:
HQ: Seattle, WA, United States
What they do:
Friends motivate one another: I'll do x if you do y.
Quick facts:
HQ: Seattle, WA, United States
There are 13 startups on this list, last updated on Oct 15, 2026.
2 of them are hiring right now, including adyn and Hubble.
By team size: VetRec (45 employees), Talus Bio (16 employees), and Rebellyous Foods (12 employees).
Latest rounds: Bonum Therapeutics — $26.9M Equity (Apr 2026).